Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Mergers and Acquisitions

Curis (CRIS) PT Raised to $18 at SunTrust Robinson HumphreyMay 31, 2018 1:38 PM Curis Announces FDA Fast Track Designation for Fimepinostat (CUDC-907) Development in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaMay 31, 2018 7:00 AM